mRNA vaccine platform demonstrates potent immunotherapeutic targeting of amyloid-beta and tau pathologies in Alzheimer's disease (PRJCA046461)
In this project, we aimed to answer the key question of whether an mRNA-based approach can specifically target and mitigate the pathological hallmarks of Alzheimer's disease (AD), such as amyloid-ß plaques and neurofibrillary tangles. Through a series of rigorous preclinical experiments, our major findings reveal that the developed mRNA vaccine successfully induces a robust and specific immune response against these pathological markers. Importantly, in animal models of AD, administration of the vaccine led to a significant reduction in amyloid plaque and neurofibrillary tangle deposition and improved cognitive function, without triggering excessive neuroinflammation - a common concern with many immunotherapeutic approaches.The most crucial conclusion drawn from our research is that mRNA vaccines hold great promise as a novel, safe, and effective therapeutic strategy for AD, offering a potential breakthrough.